## Arthur Cho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1758625/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. Journal of Nuclear Medicine, 2005, 46, 1582-8.	5.0	117
2	High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 2426-2432.	7.0	85
3	Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. Biomaterials, 2014, 35, 2272-2282.	11.4	84
4	Prognostic Value of Total Lesion Glycolysis by <sup>18</sup> F-FDG PET/CT in Surgically Resected Stage IA Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2015, 56, 45-49.	5.0	77
5	The Utility of F-18 FDG PET/CT in the Evaluation of Pancreatic Intraductal Papillary Mucinous Neoplasm. Clinical Nuclear Medicine, 2010, 35, 776-779.	1.3	66
6	The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1898-1906.	6.4	63
7	Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer, 2016, 16, 224.	2.6	54
8	Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer. Annals of Nuclear Medicine, 2016, 30, 104-113.	2.2	53
9	Surgical completeness of robotic thyroidectomy: a prospective comparison with conventional open thyroidectomy in papillary thyroid carcinoma patients. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1068-1075.	2.4	52
10	Thyroid Incidentalomas Identified by <sup>18</sup> F-FDG PET: Sonographic Correlation. American Journal of Roentgenology, 2008, 191, 598-603.	2.2	50
11	Visually Discernible [18F]Fluorodeoxyglucose Uptake in Papillary Thyroid Microcarcinoma: A Potential New Risk Factor. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3182-3188.	3.6	43
12	Clinical Usefulness of 18F-Fluorodeoxyglucose-Positron Emission Tomography in Patients With Locally Advanced Pancreatic Cancer Planned to Undergo Concurrent Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 126-133.	0.8	41
13	The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy. Nuclear Medicine and Molecular Imaging, 2014, 48, 130-136.	1.0	34
14	The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer, 2018, 21, 213-224.	5.3	32
15	Value of 18F-FDG PET/CT for Predicting the World Health Organization Malignant Grade of Thymic Epithelial Tumors. Clinical Nuclear Medicine, 2016, 41, 15-20.	1.3	29
16	Prognostic Value of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer. Yonsei Medical Journal, 2013, 54, 1377.	2.2	28
17	Prognostic value of pretreatment FDG PET in pediatric neuroblastoma. European Journal of Radiology, 2015, 84, 2633-2639.	2.6	26
18	The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Annals of Nuclear Medicine, 2015, 29, 400-408.	2.2	25

Arthur Cho

#	Article	IF	CITATIONS
19	Regulation of Acetate Utilization by Monocarboxylate Transporter 1 (MCT1) in Hepatocellular Carcinoma (HCC). Oncology Research, 2018, 26, 71-81.	1.5	25
20	Clinicopathologic Features and Molecular Characteristics of Glucose Metabolism Contributing to ¹â <del>,F</del> -fluorodeoxyglucose Uptake in Gastrointestinal Stromal Tumors. PLoS ONE, 2015, 10, e0141413.	2.5	25
21	Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. European Radiology, 2011, 21, 1077-1087.	4.5	23
22	18F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. Annals of Nuclear Medicine, 2014, 28, 304-313.	2.2	23
23	Thyroid incidentalomas detected onÂ18F-fluorodeoxyglucose-positron emission tomography/computed tomography: Thyroid Imaging Reporting and Data System (TIRADS) in the diagnosis and management ofÂpatients. Surgery, 2015, 158, 1314-1322.	1.9	23
24	Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non–Small Cell Lung Cancer. Clinical Nuclear Medicine, 2016, 41, 347-353.	1.3	23
25	Physiologic <sup>18</sup> F-FDG Uptake in the Fallopian Tubes at Mid Cycle on PET/CT. Journal of Nuclear Medicine, 2010, 51, 682-685.	5.0	22
26	Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. Nuclear Medicine and Molecular Imaging, 2012, 46, 169-175.	1.0	21
27	Clinical correlations with 18FDG PET scan patterns in solid pseudopapillary tumors of the pancreas: Still a surgical enigma?. Pancreatology, 2014, 14, 515-523.	1.1	21
28	Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer. Abdominal Radiology, 2017, 42, 1621-1626.	2.1	19
29	Serum glucose excretion after Roux-en-Y gastric bypass: a potential target for diabetes treatment. Gut, 2021, 70, 1847-1856.	12.1	19
30	Usefulness of SPECT/CT in Parathyroid Lesion Detection in Patients with Thyroid Parenchymal 99mTc-Sestamibi Retention. Nuclear Medicine and Molecular Imaging, 2017, 51, 32-39.	1.0	17
31	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Annals of Nuclear Medicine, 2016, 30, 279-286.	2.2	16
32	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. Gastric Cancer, 2019, 22, 113-122.	5.3	16
33	Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology, 2020, 27, 197-205.e6.	5.2	16
34	Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer1. Lung Cancer, 2020, 142, 28-33.	2.0	16
35	Intestinal Glycolysis Visualized by FDG PET/CT Correlates With Glucose Decrement After Gastrectomy. Diabetes, 2017, 66, 385-391.	0.6	14
36	Evaluation of 18F-FDG PET/CT Parameters for Detection of Lymph Node Metastasis in Cutaneous Melanoma. Nuclear Medicine and Molecular Imaging, 2018, 52, 39-45.	1.0	14

Arthur Cho

#	Article	IF	CITATIONS
37	Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Cell Reports, 2022, 38, 110236.	6.4	14
38	Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using 18F-FDG PET/CT and 99mTc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation. Nuclear Medicine and Molecular Imaging, 2011, 45, 203-211.	1.0	13
39	Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer. Journal of Nuclear Medicine, 2015, 56, 1494-1500.	5.0	13
40	Measurement of Donor Kidney Functional Renal Volume and Glomerular Filtration Rate to Predict Allograft Function during the Post-Transplantation Period. Nephron Clinical Practice, 2009, 113, c262-c269.	2.3	12
41	The Performance of Contrast-Enhanced FDG PET/CT for the Differential Diagnosis of Unexpected Ovarian Mass Lesions in Patients With Nongynecologic Cancer. Clinical Nuclear Medicine, 2015, 40, 97-102.	1.3	12
42	Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer. Nuclear Medicine and Molecular Imaging, 2015, 49, 108-114.	1.0	12
43	Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1984-1994.	6.4	12
44	Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 561-571.	6.4	12
45	Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Pharmacogenetics and Genomics, 2016, 26, 116-125.	1.5	11
46	STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [ <sup>18</sup> F]FLT PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	11
47	Using 18F-FDG PET/CT to Detect an Occult Mesenchymal Tumor Causing Oncogenic Osteomalacia. Nuclear Medicine and Molecular Imaging, 2011, 45, 233-237.	1.0	10
48	Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer. Nuclear Medicine and Molecular Imaging, 2013, 47, 257-262.	1.0	10
49	Feasibility of Preoperative FDG PET/CT Total Hepatic Glycolysis in the Remnant Liver for the Prediction of Postoperative Liver Function. American Journal of Roentgenology, 2017, 208, 624-631.	2.2	10
50	Association of high metabolic activity measured by positron emission tomography imaging with poor prognosis of choroidal melanoma. British Journal of Ophthalmology, 2011, 95, 1588-1591.	3.9	9
51	Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors. Cancer & Metabolism, 2021, 9, 8.	5.0	9
52	Splenic uptake on FDG PET/CT correlates with Kikuchi-Fujimoto disease severity. Scientific Reports, 2021, 11, 10836.	3.3	8
53	Increased hepatic FDG uptake on PET/CT in hepatic sinusoidal obstructive syndrome. Oncotarget, 2016, 7, 69024-69031.	1.8	8
54	The Additional Value of Attenuation Correction CT Acquired During 18F-FDG PET/CT in Differentiating	1.3	7

ARTHUR CHO

#	Article	IF	CITATIONS
55	Association Between Choroidal Thickness and Metabolic Activity on Positron Emission Tomography in Eyes With Choroidal Melanoma. American Journal of Ophthalmology, 2015, 160, 1111-1115.e2.	3.3	7
56	Predicting treatment outcomes using <sup>18</sup> F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	3.2	7
57	NSCLC Subtype Prediction Using Cytologic Fluid Specimens From Needle Aspiration Biopsies. American Journal of Clinical Pathology, 2013, 139, 309-316.	0.7	6
58	64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model. PLoS ONE, 2015, 10, e0131083.	2.5	6
59	A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas. Cancer Research and Treatment, 2016, 48, 409-414.	3.0	6
60	Evaluation of 18F-FDG Excretion Patterns in Malignant Obstructive Uropathy. Clinical Nuclear Medicine, 2013, 38, 695-702.	1.3	5
61	REGRESSION OF UVEAL MELANOMA AFTER RU-106 BRACHYTHERAPY AND THERMOTHERAPY BASED ON METABOLIC ACTIVITY MEASURED BY POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY. Retina, 2014, 34, 182-187.	1.7	5
62	Choroid Plexus as the Best Reference Region for Standardized Uptake Value Analysis on C11-Acetate PET/CT for Grading and Predicting Prognosis in Patients with Cerebral Gliomas. Nuclear Medicine and Molecular Imaging, 2020, 54, 274-280.	1.0	5
63	18F-fluoride PET imaging in a nude rat model of bone metastasis from breast cancer: Comparison with 18F-FDG and bioluminescence imaging. Nuclear Medicine and Biology, 2015, 42, 728-733.	0.6	4
64	Altered systematic glucose utilization after gastrectomy: correlation with weight loss. Surgery for Obesity and Related Diseases, 2020, 16, 900-907.	1.2	4
65	Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer. Tumor Biology, 2016, 37, 3205-3213.	1.8	3
66	Prognostic Impact of Ultrasonography Features and <sup>18</sup> F-Fluorodeoxyglucose Uptake in Patients With Papillary Thyroid Microcarcinoma. Clinical and Experimental Otorhinolaryngology, 2016, 9, 62-69.	2.1	3
67	Predictive value of bone scintigraphy for the detection of joint involvement in Behçet's disease: Dermatologists' perspectives. European Journal of Dermatology, 2015, 25, 477-482.	0.6	2
68	Radiologic Diagnosis (CT, MRI, & PET-CT). , 2019, , 67-86.		1
69	Profile of vascular markers and CT enhancement of hyaline vascular type Castleman's disease. Microvascular Research, 2022, 142, 104357.	2.5	1
70	Altered Glucose Metabolism and Glucose Transporters in Systemic Organs After Bariatric Surgery. Frontiers in Endocrinology, 0, 13, .	3.5	1
71	Reply to Letter to Editor re: usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. European Radiology, 2011, 21, 2150-2150.	4.5	0
72	Reply. American Journal of Ophthalmology, 2016, 163, 198-199.	3.3	0

ARTHUR CHO

#	Article	IF	CITATIONS
73	Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. Korean Journal of Internal Medicine, 2021, 36, S245-S252.	1.7	0
74	Radiation Safety Issues Related to Sentinel Lymph Node Biopsy using Radioactive Colloid: Commentary on "Exposure of Surgical Staff to Radiation". Journal of Breast Cancer, 2009, 12, 121.	1.9	0
75	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer Journal of Clinical Oncology, 2015, 33, 4113-4113.	1.6	0